Avecia Biologics

News Avecia Biologics

UK consortium led by Paraytec Ltd to develop analytical instrumentation to detect aggregation in biopharmaceutical processing

A multi-disciplinary UK consortium of partners including Avecia, Intertek ASG, Lonza, Paraytec and the University of Bradford has recently been awarded research grants by the Technology Strategy Board and the Engineering and Physical Sciences Research Council. The part funded £1M+ project is to deve more
Avecia completes sale of its Electronic Materials businesses

Avecia announced that it has completed the sale of its Electronic Materials businesses (Ink jet and Electrophotography) to FUJIFILM, having obtained all necessary approvals. This successfully concludes a sale agreement previously announced on 26th December 2005. The disposal includes all Avecia Ink more
Avecia completes sales of its Pharmaceuticals business unit

Avecia announced that it has completed the sale of its Pharmaceuticals custom synthesis business to Nicholas Piramal India Limited (NPIL), having obtained all necessary approvals. This successfully concludes a sale agreement previously announced on 27th October 2005. NPIL has paid GBP 9.5 million i more

OligoMedicines Biologics News Investors Extranet Expertise. Innovation. Commitment. Avecia is a leading private biotechnology company focused on the development and manufacture of innovative biotechnology-based medicines. With a long history of technological innovation, we work closely with our cu more

Management

Marine Natural Products About us » The Company » Development Programme » Our Team » Company History » Contact us Core technology R & D Pharmaceuticals Consumer Health News Contact us Management | Our Team CEO Professor Simon G Best OBE FRSE Professor Simon Best has over 25 years experience across th more